Kirsteen MacClean, PhD
Senior Director Scientific Brand Strategy
FlexVUE case studies
Length: 20 minutes
Relevant for
FlexVUE, InSituPlex
Description In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
Meet the host
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Quickly customize your immune profiling assay to discover the biology most relevant to you.
Related Content
Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit
Presented at EASL 2021
Overview of the differences between standard IHC and multiplexed immunofluoresence
Ultivue
Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors
Length: 60 minutes
